Related references
Note: Only part of the references are listed.Antidepressant-like effects of buprenorphine in rats are strain dependent
Caroline A. Browne et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin/kappa-opioid receptor system
Rachel J. Donahue et al.
BEHAVIOURAL PHARMACOLOGY (2015)
Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice
Abdulrahman Almatroudi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic
Jeffrey J. Buda et al.
NEUROPSYCHOPHARMACOLOGY (2015)
How fast and how often: The pharmacokinetics of drug use are decisive in addiction
Florence Allain et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2015)
Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans
Anya K. Bershad et al.
PSYCHONEUROENDOCRINOLOGY (2015)
Abnormal error processing in depressive states: a translational examination in humans and rats
C. Beard et al.
TRANSLATIONAL PSYCHIATRY (2015)
BU08073 a buprenorphine analogue with partial agonist activity at mu-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice
T. V. Khroyan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Circumspectives: The Promise of Ketamine
William A. Carlezon et al.
NEUROPSYCHOPHARMACOLOGY (2015)
Evaluation of Opioid Modulation in Major Depressive Disorder
Elliot Ehrich et al.
NEUROPSYCHOPHARMACOLOGY (2015)
Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice
Edgardo Falcon et al.
PSYCHOPHARMACOLOGY (2015)
A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm
Sarah F. Cordery et al.
ADDICTION BIOLOGY (2014)
Antagonists of the kappa opioid receptor
Mariangela Urbano et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults
Jordan F. Karp et al.
JOURNAL OF CLINICAL PSYCHIATRY (2014)
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders
Linda M. Rorick-Kehn et al.
NEUROPHARMACOLOGY (2014)
Development of κ Opioid Receptor Antagonists
F. Ivy Carroll et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Prefrontal Cortical Kappa-Opioid Receptor Modulation of Local Neurotransmission and Conditioned Place Aversion
Hugo A. Tejeda et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Role of kappa-opioid receptors in stress and anxiety-related behavior
Ashlee Van't Veer et al.
PSYCHOPHARMACOLOGY (2013)
Roles of Nucleus Accumbens CREB and Dynorphin in Dysregulation of Motivation
John W. Muschamp et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2013)
The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety
Jesse R. Schank et al.
ADDICTION BIOLOGY (2012)
Stress Produces Aversion and Potentiates Cocaine Reward by Releasing Endogenous Dynorphins in the Ventral Striatum to Locally Stimulate Serotonin Reuptake
Abigail G. Schindler et al.
JOURNAL OF NEUROSCIENCE (2012)
Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats
Elena Chartoff et al.
NEUROPHARMACOLOGY (2012)
Corticotropin-Releasing Factor (CRF)-Induced Disruption of Attention in Rats Is Blocked by the κ-Opioid Receptor Antagonist JDTic
Ashlee Van't Veer et al.
NEUROPSYCHOPHARMACOLOGY (2012)
A Combination of Buprenorphine and Naltrexone Blocks Compulsive Cocaine Intake in Rodents Without Producing Dependence
Sunmee Wee et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Kappa Opioid Receptor Signaling in the Basolateral Amygdala Regulates Conditioned Fear and Anxiety in Rats
Allison T. Knoll et al.
BIOLOGICAL PSYCHIATRY (2011)
Repeated Exposure to the κ-Opioid Receptor Agonist Salvinorin A Modulates Extracellular Signal-Regulated Kinase and Reward Sensitivity
David N. Potter et al.
BIOLOGICAL PSYCHIATRY (2011)
Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity
Matthew F. Peters et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Activation of CREB in the Nucleus Accumbens Shell Produces Anhedonia and Resistance to Extinction of Fear in Rats
John W. Muschamp et al.
JOURNAL OF NEUROSCIENCE (2011)
Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation
Erica J. Melief et al.
MOLECULAR PHARMACOLOGY (2011)
Pharmacological Characterization of 2-Methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a High-Affinity Antagonist Selective for κ-Opioid Receptors
S. Grimwood et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders
Thomas Insel et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Dynorphin, stress, and depression
Allison T. Knoll et al.
BRAIN RESEARCH (2010)
The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors
M. R. Bruchas et al.
BRAIN RESEARCH (2010)
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse
Sunmee Wee et al.
PSYCHOPHARMACOLOGY (2010)
Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats
Gregory V. Carr et al.
PSYCHOPHARMACOLOGY (2010)
Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens
Stephanie R. Ebner et al.
PSYCHOPHARMACOLOGY (2010)
kappa-Opioid receptor signaling and brain reward function
Adrie W. Bruijnzeel
BRAIN RESEARCH REVIEWS (2009)
Desipramine Reduces Stress-Activated Dynorphin Expression and CREB Phosphorylation in NAc Tissue
Elena H. Chartoff et al.
MOLECULAR PHARMACOLOGY (2009)
Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis
William A. Carlezon et al.
NEUROPHARMACOLOGY (2009)
Perspective Progress on the Study and Treatment of Depressive Illness
William A. Carlezon et al.
NEUROPSYCHOPHARMACOLOGY (2009)
CRF1-R Activation of the Dynorphin/Kappa Opioid System in the Mouse Basolateral Amygdala Mediates Anxiety-Like Behavior
Michael R. Bruchas et al.
PLOS ONE (2009)
Kappa-opioid ligands in the study and treatment of mood disorders
William A. Carlezon et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action
Jane V. Aldrich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The Kappa-Opioid Agonist U69,593 Blocks Cocaine-Induced Enhancement of Brain Stimulation Reward
Hilarie C. Tomasiewicz et al.
BIOLOGICAL PSYCHIATRY (2008)
Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders
D. J. McCann
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy
Peter W. Nyhuis et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
The dysphoric component of stress is encoded by activation of the dynorphin κ-opioid system
Benjamin B. Land et al.
JOURNAL OF NEUROSCIENCE (2008)
Pharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence
Brendan M. Walker et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Anxiolytic-Like effects of κ-opioid receptor antagonists in models of unlearned and learned fear in rats
Allison T. Knoll et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn
A. N. Carey et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze
Dominique Drapier et al.
BEHAVIOURAL BRAIN RESEARCH (2007)
Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation
William A. Carlezon et al.
NATURE PROTOCOLS (2007)
Naltrexone and buprenorphine combination in the treatment of opioid dependence
G. Gerra et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
The mesolimbic dopamine reward circuit in depression
Eric J. Nestler et al.
BIOLOGICAL PSYCHIATRY (2006)
Hippocampal neurogenesis: Regulation by stress and antidepressants
Alex Dranovsky et al.
BIOLOGICAL PSYCHIATRY (2006)
Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats
WA Carlezon et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Cure therapeutics and strategic prevention: raising the bar for mental health research
TR Insel et al.
MOLECULAR PSYCHIATRY (2006)
Effects of JDTic, a selective κ-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model
FI Carroll et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats
PM Beardsley et al.
PSYCHOPHARMACOLOGY (2005)
Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist
MA Bennett et al.
JOURNAL OF PEPTIDE RESEARCH (2005)
Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats
MS Todtenkopf et al.
PSYCHOPHARMACOLOGY (2004)
Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects
Y Shirayama et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence
ID Montoya et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Dopaminergic mechanisms in the conditioned and unconditioned fear as assessed by the two-way avoidance and light switch-off tests
FLV Reis et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2004)
Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats
SD Mague et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys
SS Negus et al.
PSYCHOPHARMACOLOGY (2002)
Major coexpression of κ-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles
AL Svingos et al.
SYNAPSE (2001)
Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
SL Walsh et al.
PSYCHOPHARMACOLOGY (2001)
Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect
ACH Chen et al.
BIOLOGICAL PSYCHIATRY (2001)
Potent and selective indolomorphinan antagonists of the kappa-opioid receptor
WC Stevens et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
5′-guanidinonaltrindole, a highly selective and potent κ-opioid receptor antagonist
RM Jones et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence
RB Rothman et al.
JOURNAL OF SUBSTANCE ABUSE TREATMENT (2000)
Share Paper
